Coherus Biosciences | CHRS - Capitaux D'Emprunt





Capitaux D'Emprunt Changement Date
AbbVie USD 64.53B 5.59B 2026-03
Acadia Pharmaceuticals USD 0 0 2025-03
Akebia Therapeutics USD 24.75M 11.64M 2026-06
ALKERMES USD 1.48B 7.23M 2026-06
Alnylam Pharmaceuticals USD 2.47B 6.56M 2026-06
Amgen USD 51.86B 27M 2026-06
Baxter International USD 8.62B 6M 2026-06
Biogen USD 7.29B 1B 2026-06
BioMarin Pharmaceutical USD 3.53B 2.1B 2026-06
Bristol-Myers Squibb USD 42.09B 59M 2026-06
Coherus Biosciences USD 51.08M 496K 2025-12
Eli Lilly USD 47.86B 8.49B 2026-06
Fujifilm JPY 607.03B 35.21B 2026-03
Gilead Sciences USD 20.86B 1.27B 2026-03
Ironwood Pharmaceuticals USD 583.99M 14.83M 2024-12
Merck USD 51.08B 4.41B 2026-06
Myriad Genetics USD 120.7M 400K 2026-06
Pacira USD 363.12M 4.53M 2026-06
Perrigo USD 3.28B 337.7M 2026-06
Pfizer USD 60.5B 70M 2026-06
PTC Therapeutics USD 535.52M 248.58M 2026-06
Regeneron Pharmaceuticals USD 1.99B 400K 2026-06
Sarepta Therapeutics USD 847.62M 9.46M 2026-06
Teva Pharmaceutical Industries USD 12.09B 1.92B 2026-06
Vertex Pharmaceuticals USD 106.7M 4.7M 2025-12
Xencor USD 77.54M 4.59M 2026-06
Zoetis USD 9.05B 3M 2026-06